33629327|t|Haloperidol for preventing delirium in ICU patients: a systematic review and meta-analysis.
33629327|a|OBJECTIVE: Delirium, a common behavioral manifestation of acute brain dysfunction in Intensive Care Unit (ICU), is a significant contributor to mortality and worse long-term outcome. Antipsychotics, especially haloperidol, are commonly administered for the treatment and prevention of delirium in critically ill patients while the evidence for the safety and efficacy of these drugs is still lacking. Therefore, we conducted a systematic review of the benefits of haloperidol for the prevention of delirium in ICU patients. MATERIALS AND METHODS: We made a systematic review and meta-analysis. RESULTS: Eight RCTs with 2806 patients were included. The prophylactic use of haloperidol did not reduce the delirium incidence (RR: 0.90, 95% CI: 0.69-1.71), the duration of delirium (MD: -0.33, 95% CI: -1.25-0.588) and the delirium/coma free days (MD: 0.08, 95% CI: -0.06-0.23). We did not find an increase of extrapyramidal effects (RR: 1.86, 95% CI: 0.30-11.39), QTc prolongation (RR: 1.11, 95% CI: 0.79-1.55) and arrhythmias (RR: 1.26, 95% CI: 0.72-2.19). The use of haloperidol did not increase the ICU (MD: 0.77, 95% CI: -0.28-1.83) and hospital length of stay (MD: -0.57, 95% CI: -1.32-0.18). Haloperidol did not increase the sedation level (RR: 1.88, 95% CI: 0.76-4.63) and mortality (RR: 0.97, 95% CI: 0.83-1.18). CONCLUSIONS: Haloperidol did not reduce the delirium incidence, the delirium duration, the delirium/coma free-days and did not increase the incidence of extrapyramidal effects, arrhythmias, the ICU and hospital length of stays and sedation.
33629327	0	11	Haloperidol	Chemical	MESH:D006220
33629327	27	35	delirium	Disease	MESH:D003693
33629327	43	51	patients	Species	9606
33629327	103	111	Delirium	Disease	MESH:D003693
33629327	156	173	brain dysfunction	Disease	MESH:D001927
33629327	302	313	haloperidol	Chemical	MESH:D006220
33629327	377	385	delirium	Disease	MESH:D003693
33629327	389	403	critically ill	Disease	MESH:D016638
33629327	404	412	patients	Species	9606
33629327	556	567	haloperidol	Chemical	MESH:D006220
33629327	590	598	delirium	Disease	MESH:D003693
33629327	606	614	patients	Species	9606
33629327	716	724	patients	Species	9606
33629327	764	775	haloperidol	Chemical	MESH:D006220
33629327	795	803	delirium	Disease	MESH:D003693
33629327	861	869	delirium	Disease	MESH:D003693
33629327	911	919	delirium	Disease	MESH:D003693
33629327	920	924	coma	Disease	MESH:D003128
33629327	998	1020	extrapyramidal effects	Disease	MESH:D001480
33629327	1053	1069	QTc prolongation	Disease	MESH:D008133
33629327	1104	1115	arrhythmias	Disease	MESH:D001145
33629327	1158	1169	haloperidol	Chemical	MESH:D006220
33629327	1287	1298	Haloperidol	Chemical	MESH:D006220
33629327	1423	1434	Haloperidol	Chemical	MESH:D006220
33629327	1454	1462	delirium	Disease	MESH:D003693
33629327	1478	1486	delirium	Disease	MESH:D003693
33629327	1501	1509	delirium	Disease	MESH:D003693
33629327	1510	1514	coma	Disease	MESH:D003128
33629327	1563	1585	extrapyramidal effects	Disease	MESH:D001480
33629327	1587	1598	arrhythmias	Disease	MESH:D001145
33629327	Negative_Correlation	MESH:D006220	MESH:D016638
33629327	Negative_Correlation	MESH:D006220	MESH:D003693

